Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.
Khoury
Hanna Jean
HJ
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA. hkhoury@emory.edu
Guilhot
François
F
Hughes
Timothy P
TP
Kim
Dong-Wook
DW
Cortes
Jorge E
JE
D002986:Clinical Trials as Topic; D000075202:Contraindications; D000069439:Dasatinib; D004347:Drug Interactions; D041981:Gastrointestinal Tract / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010996:Pleural Effusion / Q000139:chemically induced; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*
D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib